1ZLI image
Entry Detail
PDB ID:
1ZLI
Title:
Crystal structure of the tick carboxypeptidase inhibitor in complex with human carboxypeptidase B
Biological Source:
Host Organism:
PDB Version:
Deposition Date:
2005-05-06
Release Date:
2005-07-05
Method Details:
Experimental Method:
Resolution:
2.09 Å
R-Value Free:
0.21
R-Value Work:
0.15
R-Value Observed:
0.15
Space Group:
P 43 21 2
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Carboxypeptidase B
Chain IDs:A
Chain Length:309
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:carboxypeptidase inhibitor
Chain IDs:B
Chain Length:75
Number of Molecules:1
Biological Source:Rhipicephalus bursa
Ligand Molecules
Primary Citation
The Three-Dimensional Structures of Tick Carboxypeptidase Inhibitor in Complex with A/B Carboxypeptidases Reveal a Novel Double-headed Binding Mode
J.Mol.Biol. 350 489 498 (2005)
PMID: 15961103 DOI: 10.1016/j.jmb.2005.05.015

Abstact

The tick carboxypeptidase inhibitor (TCI) is a proteinaceous inhibitor of metallo-carboxypeptidases present in the blood-sucking tick Rhipicephalus bursa. The three-dimensional crystal structures of recombinant TCI bound to bovine carboxypeptidase A and to human carboxypeptidase B have been determined and refined at 1.7 A and at 2.0 A resolution, respectively. TCI consists of two domains that are structurally similar despite the low degree of sequence homology. The domains, each consisting of a short alpha-helix followed by a small twisted antiparallel beta-sheet, show a high level of structural homology to proteins of the beta-defensin-fold family. TCI anchors to the surface of mammalian carboxypeptidases in a double-headed manner not previously seen for carboxypeptidase inhibitors: the last three carboxy-terminal amino acid residues interact with the active site of the enzyme in a way that mimics substrate binding, and the N-terminal domain binds to an exosite distinct from the active-site groove. The structures of these complexes should prove valuable in the applications of TCI as a thrombolytic drug and as a basis for the design of novel bivalent carboxypeptidase inhibitors.

Legend

Protein

Chemical

Disease

Primary Citation of related structures